Default company panoramic image
Logo

Definigen Ltd

Definigen provide pharma with optimised stem cell derived liver and pancreatic products to improve the economics of drug discovery

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Cambridge, England, GB
  • Currency USD
  • Founded April 2012
  • Employees 4
  • Website definigen.com

Company Summary

DefiniGEN is a supplier of human liver and pancreatic cells for preclinical drug discovery and disease modelling using human Induced Pluripotent Stem Cells (hIPSC). The resulting products deliver major benefits for the pharmaceutical sector by providing human cells which can offer maximum predictivity of the efficacy and safety of compounds through the drug development process

Team

  • Default avatar
    Ludovic Vallier
    CSO

  • Default avatar
    Alastair Riddell
    Chairman

  • Default avatar
    Marcus Yeo
    CEO

  • Default avatar
    Jonathan Milner
    Board Observer

  • Default avatar
    Giorgio Reggiani
    CFO

  • Default avatar
    Bradley Hardiman
    NED

Advisors

  • Default avatar
    Mills & Reeve LLP
    Lawyer
    Unconfirmed
    Default avatar
    Barnbrook Sinclair
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    University of Cambridge, Jonathan Milner, Herman Hauser, CCG
    Unconfirmed